Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23890773 | 1.00 | USP2 (0.57) | USP2SMN1; SMN2RECQLPDK1NR1H2 | |
| SCHEMBL1515253 | 1.00 | USP2 (0.57) | USP2SMN1; SMN2RECQLPDK1NR1H2 | |
| SCHEMBL30599898 | 0.88 | RECQL (0.53) | USP2SMN1; SMN2RECQLPDK1NR1H2 | |
| SCHEMBL23380189 | 0.85 | RECQL (0.60) | USP2SMN1; SMN2RECQLHPGDMAPT | |
| SCHEMBL28459828 | 0.83 | USP2 (0.57) | USP2SMN1; SMN2RECQLNR1H2HPGD | |
| SCHEMBL16975387 | 0.83 | USP2 (0.57) | USP2SMN1; SMN2RECQLNR1H2HPGD | |
| SCHEMBL21279710 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2RECQLNR1H2HPGD | |
| SCHEMBL20233118 | 0.82 | USP2 (0.60) | USP2SMN1; SMN2RECQLNR1H2HPGD | |
| SCHEMBL1515250 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2RECQLNR1H2HPGD | |
| SCHEMBL28521064 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2RECQLNR1H2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2020-12-17 | — | — | US | disclosed |
| EP-3057969-B1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORP (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2951177-B1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NEOMED INST (CA) | 2018-04-04 | — | — | EP | disclosed |
| US-9814725-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-11-14 | — | — | US | disclosed |
| WO-2017174621-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017112719-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9598409-B2 | Imidazopyridine compounds and uses thereof | NEOMED INSTITUTE (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20160102097-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2016-04-14 | — | — | US | disclosed |
| US-9200002-B2 | Compositions useful for treating disorders related to KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150111887-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102097-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | USP2 1513/4885SMN1; SMN2 172/4885RECQL 25/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | USP2 32/4885SMN1; SMN2 3149/4885RECQL 666/4885 |
| US-20200390779-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885 |
| US-20150111887-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, MSH2 | USP2 1513/4885SMN1; SMN2 172/4885RECQL 25/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885 |
| US-20220062290-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885RECQL 2866/4885 |
| US-20170143730-A1 | Imidazopyridine Compounds and Uses Thereof | NISCH, ABL1, PAICS | USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885 |
| US-20210228588-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | USP2 4058/4885SMN1; SMN2 1459/4885RECQL 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.